{
    "clinical_study": {
        "@rank": "126074", 
        "arm_group": {
            "arm_group_label": "Pracinostat with azacitadine", 
            "arm_group_type": "Experimental", 
            "description": "60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and effectiveness of pracinostat when\n      combined with azacitadine for patients who are 65 years of age or older and have Acute\n      Myelogenous Leukemia (AML)"
        }, 
        "brief_title": "Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects aged \u226565 years.\n\n          -  Voluntary written informed consent before performance of any study related procedure\n             not part of normal medical care.\n\n          -  Newly diagnosed de novo, secondary, or treatment-related AML with intermediate or\n             unfavorable-risk cytogenetics based on the Southwest Oncology Group (SWOG)\n             classifications (Slovak et al, 2000).\n\n          -  One prior cycle of therapy with an approved hypomethylating agent (HMA) such as\n             azacitidine or decitabine is allowed for either an antecedent hematologic disorder\n             (AHD) or AML. Patients are also eligible if they have received lenolidamide,\n             immunosuppressive therapy or low dose chemotherapy for their AHD. Prior hydroxyurea\n             is allowed.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n\n          -  \u226520% blasts in bone marrow.\n\n          -  Peripheral WBC <30,000/uL.\n\n          -  Adequate organ function as evidenced by:\n\n          -  Total bilirubin 2x upper limit of normal (ULN)\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)2.5x ULN\n\n          -  Serum creatinine 2x ULN\n\n          -  QT interval corrected according to Fridericia's formula (QTcF) \u2264450 milliseconds (ms)\n             for male subjects or \u2264470 ms for female subjects on ECG at Screening.\n\n          -  Male subjects who are surgically sterile or willing to use adequate contraceptive\n             measures or abstain from heterosexual intercourse during the entire study treatment\n             period.\n\n          -  Female subjects who are not of childbearing potential.\n\n          -  Willingness and ability to understand the nature of this study and to comply with the\n             study and follow up procedures\n\n        Exclusion Criteria:\n\n          -  Acute promyelocytic leukemia (French-American-British [FAB] M3 classification).\n\n          -  Known AML-associated t(15;17), t(8;21), t(16;16), del(16q), or inv(16) karyotype\n             abnormalities.\n\n          -  Presence of a malignant disease within the last 12 months, with the exception of\n             adequately treated in-situ carcinomas, basal or squamous cell carcinoma, or\n             non-melanomatous skin cancer. Other malignancies will be considered on a case-by-case\n             basis.\n\n          -  Life-threatening illnesses other than AML, uncontrolled medical conditions or organ\n             system dysfunction that, in the Investigator's opinion, could compromise the\n             subject's safety, or put the study outcomes at risk.\n\n          -  Uncontrolled or symptomatic arrhythmias, unstable angina, or any Class 3 or 4 cardiac\n             diseases as defined by the New York Heart Association (NYHA) Functional\n             Classification.\n\n          -  Clinical evidence of central nervous system (CNS) involvement.\n\n          -  Are candidates for intensive chemotherapy (induction chemotherapy, bone marrow, or\n             stem cell transplant) within the next 4 months.\n\n          -  Received more than one prior cycle of HMA, previous bone marrow transplant or other\n             intensive chemotherapy regimens for either an AHD or AML.\n\n          -  Received prior radiation therapy for extramedullary disease within 2 weeks of study\n             enrollment.\n\n          -  Received prior histone deacetylase (HDAC) inhibitor or deacetylase (DAC) inhibitor is\n             not permitted such as Istodax (romidepsin/depsipetide) or valproic acid.\n\n          -  Received hematopoietic growth factors: erythropoietin, granulocyte colony stimulating\n             factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), or\n             thrombopoietin receptor agonists within 7 days (14 days for Aranesp) prior to study\n             enrollment.\n\n          -  Have been treated with any chemotherapeutic agent within 2 weeks or 5 half-lives of\n             the first dose of study drug, whichever is longer.\n\n          -  Are being treated with systemic corticosteroids. Inhaled and topical steroids as well\n             as intermittent dexamethasone for nausea or vomiting are permitted.\n\n          -  Known history of human immunodeficiency virus (HIV) or active infection with\n             hepatitis C virus (HCV) or hepatitis B virus (HBV).\n\n          -  Uncontrolled active systemic infections.\n\n          -  Gastrointestinal (GI) tract disease, causing the inability to take oral medication,\n             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures\n             affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn's disease,\n             ulcerative colitis).\n\n          -  Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a\n             physical examination or clinical laboratory test result that would cause reasonable\n             suspicion of a disease or condition, that contraindicates the use of study drugs,\n             that may increase the risk associated with study participation, that may affect the\n             interpretation of the results, or that would make the subject inappropriate for this\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912274", 
            "org_study_id": "MEI-004"
        }, 
        "intervention": {
            "arm_group_label": "Pracinostat with azacitadine", 
            "description": "Elderly newly diagnosed patients will all receive the combination of pracinostat with azacitadine", 
            "intervention_name": "pracinostat with azacitadine", 
            "intervention_type": "Drug", 
            "other_name": "SB939"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "AML", 
            "open label", 
            "nonrandomized", 
            "single arm", 
            "elderly patients", 
            "HMA", 
            "newly diagnosed"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "link": {
            "description": "Sponsor website", 
            "url": "http://www.meipharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "hilam@coh.org", 
                    "last_name": "Pennie Lam", 
                    "phone": "626-256-4673", 
                    "phone_ext": "63192"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope Comprehensive Cancer Ctr"
                }, 
                "investigator": {
                    "last_name": "Samer Khaled, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pleasant Hill", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94523"
                    }, 
                    "name": "Bay Area Cancer Research Group"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "marlenez@stanford.edu", 
                    "last_name": "Marlene Zuraek", 
                    "phone": "650-736-4031"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5821"
                    }, 
                    "name": "Stanford University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Bruno Medeiros, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "terri.eubanks@emory.edu", 
                    "last_name": "Terri Eubanks", 
                    "phone": "404-778-4994"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Emory University"
                }, 
                "investigator": {
                    "last_name": "Martha Arrelano, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mdaunov@bsd.uchicago.edu", 
                    "last_name": "Michael Daunov", 
                    "phone": "773-834-2119"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "The University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Olatoysoi Odenike, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fryeba@iupui.edu", 
                    "last_name": "Bobbie Freye", 
                    "phone": "317-274-2992"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Inidana Univ Simon Cancer Center"
                }, 
                "investigator": {
                    "last_name": "S.Hamid Sayar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "crawley.jamie@mayo.edu", 
                    "last_name": "Jamie Crawley", 
                    "phone": "507-284-5280"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Mrinal Patnaik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pearlena.hamlet@mercy.net", 
                    "last_name": "Pearlena Hamlet", 
                    "phone": "417-820-9742"
                }, 
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65807"
                    }, 
                    "name": "Mercy Medical Research Center"
                }, 
                "investigator": {
                    "last_name": "Viran Holden, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rhoyt@unmc.edu", 
                    "last_name": "Rose Hoyt", 
                    "phone": "402-559-4810"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68198-7680"
                    }, 
                    "name": "University of Nebraska Medical Center"
                }, 
                "investigator": {
                    "last_name": "Lori Maness-Harris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marxc@ohsu.edu", 
                    "last_name": "Caitlin Marx"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Science University"
                }, 
                "investigator": {
                    "last_name": "Elie Traer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "salzers@musc.edu", 
                    "last_name": "Shanta Salzer", 
                    "phone": "843-792-1463"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical College of South Carolina-Hollings Cancer Ctr"
                }, 
                "investigator": {
                    "last_name": "Alice Mims, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "betsyw@mdanderson.org", 
                    "last_name": "Betsy Williams", 
                    "phone": "713-792-1993"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson"
                }, 
                "investigator": {
                    "last_name": "Guillermo Garcia-Manero, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hsunderraj@mcw.edu", 
                    "last_name": "Hemavathy Sunder Raj", 
                    "phone": "414-805-8970"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Medical College of Wisconsin-Froedtert Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ehab Attalah, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)", 
        "overall_contact": {
            "email": "vesquibel@meipharma.com", 
            "last_name": "Vanessa Esquibel", 
            "phone": "858-369-7174"
        }, 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Guillermo Garcia-Manero, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimate the rate of complete response (CR) + CR with incomplete blood count recovery (CRi) + morphologic leukemia free state (MLFS) to the combination of pracinostat and azacitidine.", 
            "measure": "Estimate efficacy rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912274"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimate the overall response rate (ORR) (CR + CRi + partial response [PR]\n+ PR with incomplete blood count recovery [PRi] + MLFS) to pracinostat plus azacitidine", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the rate of complete cytogenetic response (CRc) to pracinostat plus azacitidine", 
                "measure": "Complete cytogenetic response", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the rate of complete cytogenetic response (CRc) + molecular complete remission (CRm) to pracinostat plus azacitidine", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimate the progression-free survival (PFS) duration after pracinostat plus azacitidine", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Estimate the overall survival (OS) duration after pracinostat plus azacitidine", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "6 - 24 months"
            }, 
            {
                "description": "Assess the tolerability and adverse event (AE) profile of pracinostat when combined with azacitidine", 
                "measure": "Tolerability and AE profile", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "MEI Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MEI Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}